Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL
The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.
“I'm excited to see what the duration of response and progression-free survival are. The follow-up at this point is too short for that to have been presented... I'll be excited to see that [because] the CD62L-selected cells we would expect to have better persistence, which we would hope then translates into a longer duration of response and progression-free survival.”
Currently, a number of chimeric antigen receptor T-cell (CAR-T) therapies are commercially available for the treatment of large B-cell lymphoma (LBCL). Although, a number of companies and academic institutions are continuing to develop new CAR-T products for this indication, with innovations intended to provide new alternatives and overcome limitations of the current treatment options. One such product is Lyell Immunopharma’s IMPT-314, a CD19/CD20 dual-targeted autologous CAR-T therapy, which is currently being evaluated in a phase 1/2 clinical trial (NCT05826535) for the treatment of relapsed/refractory LBCL in patients who have not previously received CAR-T therapy. Initial results from patients treated in this trial were recently presentedat the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California, by Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA).
Shortly after the close of the conference, CGTLive® interviewed Larson to learn more. Larson discussed the rationale behind the design of IMPT-314, and then went over the key results that were presented, highlighting that among 17 patients evaluable for efficacy, the overall response rate was 94% (16/17), with a complete response rate of 71% (12/17) by 3 months posttreatment. In terms of safety, she noted that the toxicity profile was favorable, with no grade 3 or higher cytokine release syndrome reported, and cases of immune effector cell-associated neurotoxicity syndrome (ICANS) predominantly being grade 1 to 2. Larson also spoke about potential future plans for IMPT-314, and pointed out that the clinical trial is currently recruiting patients.
For more coverage of ASH 2024, click here.
